In this video, David Williamson reviews some of his favorite biotech firms. Many analysts have thrown their weight behind Biogen (BIIB 1.37%) and its new BG12 drug for multiple sclerosis. However, David favors Gilead (GILD -0.57%) over Biogen since Gilead has a larger, more diverse product pipeline. Celgene (CELG) is the No. 1 biotech in David's opinion since it also has blockbuster drugs but a PEG of less than 1.0. Amgen (AMGN 0.07%) is a big company with more products in development than most people realize. Overall, for value and future earnings potential, David likes Celgene the best.
You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Are these Wall Street upgrades really deserved?
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Our Most Popular Articles
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.